Principal Financial Group Inc. Has $474,000 Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Principal Financial Group Inc. reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDXFree Report) by 6.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,959 shares of the biopharmaceutical company’s stock after selling 889 shares during the quarter. Principal Financial Group Inc.’s holdings in Celldex Therapeutics were worth $474,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in shares of Celldex Therapeutics by 5.9% during the third quarter. Wellington Management Group LLP now owns 5,431,833 shares of the biopharmaceutical company’s stock worth $149,484,000 after purchasing an additional 300,406 shares during the period. Kynam Capital Management LP increased its stake in Celldex Therapeutics by 23.1% during the 3rd quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after purchasing an additional 600,000 shares in the last quarter. Vanguard Group Inc. increased its stake in Celldex Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,618,504 shares of the biopharmaceutical company’s stock valued at $72,061,000 after purchasing an additional 20,688 shares in the last quarter. Polar Capital Holdings Plc raised its holdings in Celldex Therapeutics by 0.4% during the third quarter. Polar Capital Holdings Plc now owns 2,426,756 shares of the biopharmaceutical company’s stock worth $66,784,000 after buying an additional 10,000 shares during the last quarter. Finally, Eventide Asset Management LLC lifted its stake in shares of Celldex Therapeutics by 16.1% in the third quarter. Eventide Asset Management LLC now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $44,032,000 after buying an additional 222,260 shares in the last quarter.

Insiders Place Their Bets

In other news, VP Elizabeth Crowley sold 38,597 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $33.64, for a total transaction of $1,298,403.08. Following the completion of the sale, the vice president now directly owns 9,074 shares of the company’s stock, valued at approximately $305,249.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Samuel Bates Martin sold 35,000 shares of Celldex Therapeutics stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $34.05, for a total value of $1,191,750.00. Following the sale, the chief financial officer now owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Elizabeth Crowley sold 38,597 shares of the business’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $33.64, for a total value of $1,298,403.08. Following the completion of the sale, the vice president now owns 9,074 shares in the company, valued at $305,249.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 112,316 shares of company stock valued at $3,809,309. Insiders own 3.80% of the company’s stock.

Wall Street Analyst Weigh In

CLDX has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Friday, March 22nd. Finally, Guggenheim raised their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.00.

Get Our Latest Research Report on Celldex Therapeutics

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $33.47 on Tuesday. Celldex Therapeutics, Inc. has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The firm’s 50-day simple moving average is $38.87 and its 200 day simple moving average is $38.59. The stock has a market cap of $2.21 billion, a PE ratio of -11.74 and a beta of 1.60.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. As a group, analysts predict that Celldex Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

(Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

See Also

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDXFree Report).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.